30 June 2020
Visiongain has launched a new pharma report Allergic Rhinitis Drugs Market Report 2020-2030: Forecasts by Sub-Markets (Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, Immunotherapy and Vaccines, Others), Intranasal Antihistamines (Dymista, Generic Intranasal Azelastine, Astepro, Patanase, Astelin, Others), Intranasal Corticosteroids (Flixonase/Flonase/Flonase OTC, Nasonex, Avamys/Veramyst, Rhinocort, Nasacort/Nasacort-OTC, Omnaris, Beconase/Beconaes AQ, Qnasl, Zetonna, Others), Oral Antihistamines (Allegra/Allegra-D/Allegra OTC, Claritin/Claritin OTC, Zyrtec/Zyrtec D, Xyzal, Clarinex, Allelock, Ebastel, Talion, Others), Immunotherapy and Vaccines (Staloral, Alutard SQ, Grazax/Grastek, Oralair, Ragwitek, Others), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).
Global allergic rhinitis market size was valued at US$xxx million in 2019 and is anticipated to reach US$xxx million in 2025 while growing at a CAGR of xxx% during the first half of the forecast period i.e. 2020 to 2025. The market size is further projected to reach US$xxx million by 2030 at a CAGR of xxx% from 2025 to 2030. The overall CAGR for allergic rhinitis market is expected to be xxx% from 2020 to 2030.
To access the data contained in this document please email email@example.com
Allergic rhinitis (AR) is one of the most common allergic conditions globally. It describes irritation and inflammation of the lining of the nasal passage which is caused by an allergic reaction. The typical symptoms of allergic rhinitis are sneezing, nasal congestion, itching and rhinorrhoea (runny nose). Many people with AR also experience eye symptoms (allergic conjunctivitis). Symptoms are generally seasonal, becoming worse in the spring and summer months as trees and plants release pollen.
North America currently dominates the global allergic rhinitis drugs market owing to the presence of well-developed healthcare infrastructure coupled with the presence of leading companies across the region. However, the region is anticipated to lose market share over the forecast period due to the mature market across the United States and changing preference of people from Rx to OTC medications. On the other hand, Asia Pacific region is anticipated to witness highest CAGR over the forecast period owing to growing healthcare initiatives by government bodies and rising awareness levels regarding allergies.
"Asia Pacific region is anticipated to witness the highest CAGR owing to growing disease prevalence. In Asia, this disease affects a large population, ranging from 27% in South Korea to 32% in the United Arab Emirates. This trend is anticipated to continue and will fuel market growth over the forecast period."
Industry Analyst, Visiongain 2020
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global circulating tumor cells market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the allergic rhinitis market.
For instance, recently in February 2020; Goetzpartners was mandated as exclusive M&A advisor by MERCK on the sale of ALLERGOPHARMA, the allergy business of the Healthcare division of MERCK, to Dermapharm, a leading German manufacturer of patent-free branded drugs. The transaction, which is expected to close by the end of the second quarter 2020, is subject to regulatory approval and satisfaction of other customary closing conditions.
The comprehensive market report features companies such as Merck KGaA, Stallergenes Greer, AstraZeneca, Boehringer Ingelheim International GmbH, Bayer AG, Novartis AG, GSK, Johnson & Johnson, UCB S.A., Kyowa Hakko Kirin, ALK-Abelló A/S, and Sanofi among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Germany, UK, France, Italy, Spain, Belgium, Switzerland, Japan, China, India, Brazil, Mexico, Argentina, UAE, Saudi Arabia, and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.
01 July 2020
Various research studies are currently underway, which are expected to create a competitive advantage for manufacturers to develop new and innovative and advanced software that is expected to provide a variety of additional opportunities in the perinatal clinical software market.
01 July 2020
Growing investment in target diagnosis of cardiovascular disorders, TB and diabetes drives demand for clinical laboratory testing. Clinical lab tests help in diagnosing mellitus diabetes. According to the International Diabetes Federation article published in 2019, some 463 million adults were diabetic, and it is estimated that it will reach 700 million worldwide by 2045.